NPC

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, March 29, 2024
CPS, Patient, Lung cancer, IND, Infection, Cancer, Investment, Cisplatin, Paclitaxel, Melanoma, Marketing, RNA, New chemical entity, Gentlemen's agreement, NRDL, Food, Therapeutic Goods Administration, Biologics license application, Insurance, Research, Junshi, National Medical Products Administration, TGA, FDA, NMPA, Tablet, COVID-19, NPC, Spacecraft, DSM-IV codes, Dacarbazine, Axitinib, Total, Pharmaceutical industry

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.

Key Points: 
  • SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.
  • Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022.
  • Loss attributable to owners was RMB2,282 million in 2023, representing a decrease of RMB104 million compared to the previous year.
  • This application was later approved for marketing in December 2023, marking the first and only approved perioperative therapy for lung cancer domestically.

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Retrieved on: 
Wednesday, March 13, 2024
HCC, Research, PIN, Conference call, Congress, Relative value unit, Conference, Head, Exercise, NSCLC, Risk, Patient, CHRS, Otorhinolaryngology, Biomarker, Sale, Acquisition, NCCN, NPC, Ophthalmology, IL-27, IND, Bevacizumab, OPSCC, Investigational New Drug, Investment, ESMO, GAAP, Workforce, Medicare, FDA, COGS, Total, Development, Pharmaceutical industry

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.

Key Points: 
  • UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.
  • Since commercial launch in May 2023, more than 727 accounts have ordered the Autoinjector presentation.
  • “Throughout 2023, Coherus demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer.
  • Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients

Retrieved on: 
Tuesday, March 12, 2024
Pharmacokinetics, Niemann–Pick disease, Hospital, NPC, GM2, Patient, RAINBOW, Lead, Safety, Pharmaceutical industry

Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW ( Phase 2 RAINBOW study NCT05758922 ).

Key Points: 
  • Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW ( Phase 2 RAINBOW study NCT05758922 ).
  • The randomized, double-blind, placebo-controlled study, conducted in Brazil, involved 13 patients from the age of 12 years who are affected by GM2 gangliosidosis or Niemann-Pick disease type C (NPC).
  • The aim of the RAINBOW study is to determine the safety, pharmacodynamics, and pharmacokinetics of two different doses of nizubaglustat in patients, in order to identify the target dosage for Azafaros’ planned Phase 3 pivotal studies.
  • Azafaros is grateful to the patients and their families who made the decision to participate in this study.”

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Exercise, Science, Patent, Alzheimer's disease, Patient, NPC, Therapy, CYTH, FDA, Cyclo, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
  • “Following the completion of the merger with Applied Molecular Transport, we are poised to continue building momentum and achieving the value-driving milestones ahead.
  • Net loss for the year ended December 31, 2023 was approximately $20.1 million.
  • The changes in research and development expenses resulted from the increased activity in the Company’s Phase 3 study of Trappsol® Cyclo™ for the treatment of NPC.

Nomura Introduces Nomura Capital Management as Firm Refines Focus on Investment Management Business in the Americas

Retrieved on: 
Monday, March 11, 2024
Banking, Professional Services, Finance, CIO, NHA, International finance, Investment management, Growth, Nomura Holdings, Entrepreneurship, NPC, Head, Executive Committee, NCM, Senior, NAM, Credit, Investment, Financial services

Nomura Holdings, Inc has realigned the firm’s collective asset and investment management capabilities in the Americas under the new brand Nomura Capital Management LLC (NCM).

Key Points: 
  • Nomura Holdings, Inc has realigned the firm’s collective asset and investment management capabilities in the Americas under the new brand Nomura Capital Management LLC (NCM).
  • NCM reflects an ongoing commitment to increase the impact of its investment management business to the overall results of Nomura Group.
  • The firm expects the consolidated go-to-market approach of NCM will play a vital part of Nomura Group’s growth strategy as its investment management business expands both in the Americas and globally.
  • Backed by Nomura, a century-old global financial services institution, Nomura Capital Management plays a vital part of Nomura Group’s growth strategy as its investment management business expands both in the Americas and globally.

RaySearch to present latest innovations in RayStation, RayCare and RayIntelligence at ISOP and NPC (NAPT)

Retrieved on: 
Thursday, April 4, 2024
Proton, NAPT, Conference, Proton therapy, Research, NPC, RBE, RaySearch Laboratories, Linear energy transfer, Future, National Association, LET, Medical imaging

STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.

Key Points: 
  • STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.
  • Visit us at RaySearch's table at ISOP and booth at NPC.
  • The focus during both ISOP and NPC will be on support for proton arcs and robust optimization based on linear energy transfer (LET) and adaptive therapy.
  • Marc Mlyn, President of RaySearch Americas, and David McPhail, VP of Sales for RaySearch Americas, will be present at the meetings and look forward to meeting existing and future clinical partners.

Pacsun Celebrates Anniversary on Roblox with Slick Rick Collaboration and Exclusive Merchandise

Retrieved on: 
Thursday, March 28, 2024
Culture, Partnership, PacSun, Slick Rick, Research, AI, NPC, Hip hop music, Generation Z, Creativity, Music, Multimedia, Collection, Gen

LOS ANGELES, March 28, 2024 /PRNewswire/ -- To commemorate the one-year anniversary of Pacsun Los Angeles Tycoon on Roblox, Pacsun has partnered with music icon and Hip-Hop pioneer, Slick Rick, to offer its community an exclusive virtual experience. Known for his legendary storytelling and fashion sense, Slick Rick brings his unique flair to the immersive experience, uniting the legacy of Hip Hop with the modern metaverse.

Key Points: 
  • LOS ANGELES, March 28, 2024 /PRNewswire/ -- To commemorate the one-year anniversary of Pacsun Los Angeles Tycoon on Roblox , Pacsun has partnered with music icon and Hip-Hop pioneer, Slick Rick, to offer its community an exclusive virtual experience.
  • Known for his legendary storytelling and fashion sense, Slick Rick brings his unique flair to the immersive experience, uniting the legacy of Hip Hop with the modern metaverse.
  • "Collaborating with Roblox and Pacsun is a true honor.
  • In this immersive collaboration, users have the opportunity to interact with Slick Rick's 3-D NPC digital avatar to earn exclusive digital items and rewards inspired by his iconic accessories.

Embark on Mythical Adventures - Pre-registration for "Ancient World" Begins

Retrieved on: 
Thursday, March 14, 2024
Destiny, Elixir, Element, EXP, Friends, Partner, Ancient history, Fantasy, Marriage, Growth, Dame Alice Owen's School, Blockchain, NFT, NPC, Overalls, Non-fungible token, App Store (iOS/iPadOS), Google Play, Service, Atmosphere, Ecosystem, Gold, Multimedia, AAA, IPS, Martial arts, Video game

SEOUL, South Korea, March 13, 2024 /PRNewswire/ -- Thanks to the resurgence of the GameFi market and the popularity brought by new GameFi projects, there has been a significant increase in overall GameFi activity. In 2023, Game Verse, an one-stop GameFi ecosystem, witnessed a growth in wallet users to 200,000 after a brand upgrade, making the community more active.

Key Points: 
  • It provides comprehensive support for chain game players and guilds and offers fast blockchain issuance services for traditional IPs and high-quality games.
  • The team has solid publishing capabilities in the global gaming industry and boasts a large number of globally renowned AAA-level game IPs.
  • For example, Longtu Korea has released iconic games such as "Bless Global" and "Yulgang Global", which have attracted over 10 million fans worldwide.
  • "Bless Global" is the first chain game in the Game Verse ecosystem to be issued to the market through blockchain.

Embark on Mythical Adventures - Pre-registration for "Ancient World" Begins

Retrieved on: 
Thursday, March 14, 2024
Destiny, Elixir, Element, EXP, Friends, Partner, Ancient history, Fantasy, Marriage, Growth, Dame Alice Owen's School, Blockchain, NFT, NPC, Overalls, Non-fungible token, App Store (iOS/iPadOS), Google Play, Service, Atmosphere, Ecosystem, Gold, AAA, IPS, Martial arts, Video game

SEOUL, South Korea, March 14, 2024 /PRNewswire/ -- Thanks to the resurgence of the GameFi market and the popularity brought by new GameFi projects, there has been a significant increase in overall GameFi activity. In 2023, Game Verse, an one-stop GameFi ecosystem, witnessed a growth in wallet users to 200,000 after a brand upgrade, making the community more active.

Key Points: 
  • It provides comprehensive support for chain game players and guilds and offers fast blockchain issuance services for traditional IPs and high-quality games.
  • The team has solid publishing capabilities in the global gaming industry and boasts a large number of globally renowned AAA-level game IPs.
  • For example, Longtu Korea has released iconic games such as "Bless Global" and "Yulgang Global", which have attracted over 10 million fans worldwide.
  • "Bless Global" is the first chain game in the Game Verse ecosystem to be issued to the market through blockchain.